circle

Investor & media center

Corporate Overview

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides (CPPs), a revolutionary delivery technology designed to overcome the major challenges of current gene-based therapies.

PYC believes its CPP technology provides safer, more effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which it has unveiled three preclinical stage assets.

PYC’s discovery and laboratory operations are located in Australia and the Company recently launched an expansion into the U.S. for its preclinical, clinical, regulatory and business development operations.

Corporate Overview

ASX Announcements

2021

Lead Investigational Drug Demonstrates Key Improvement
02 Mar 2021 Download PDF
Half Year Accounts and Appendix 4D
26 Feb 2021 Download PDF
PYC Expands US Executive Leadership Team
23 Feb 2021 Download PDF
Progress US Clinical Stage Company and Corporate Objectives
22 Feb 2021 Download PDF
PYC to Participate in RNA Discussion – BIO CEO Conference
11 Feb 2021 Download PDF
December 2020 Quarterly Report and Cashflow
29 Jan 2021 Download PDF
ICR Conference Presentation
14 Jan 2021 Download PDF
PYC to Present at ICR Westwicke Conference
06 Jan 2021 Download PDF

2020

Letter to Shareholders from the US CEO
14 Dec 2020 Download PDF
Appointment of Chief Executive Officer in the United States
10 Dec 2020 Download PDF
Change in substantial holding – Change in substantial holding
18 Nov 2020 Download PDF
Retail Entitlement Offer Share Issue and Appendix 2A
18 Nov 2020 Download PDF
Completion of Retail Entitlement Offer
13 Oct 2020 Download PDF
New Drug for Substantial Unmet Need Added to Pipeline
12 Oct 2020 Download PDF
Technical Presentation – October 2020
09 Oct 2020 Download PDF
Notice of Directors intention not to seek re election at AGM
09 Oct 2020 Download PDF
Investor Call 15th Oct 2020 12pm AEDT 9am AWST
09 Oct 2020 Download PDF
Cancellation of Unlisted Options
09 Oct 2020 Download PDF
PYC’s Lead Drug Effective in Patient Derived Models Tested
07 Oct 2020 Download PDF
Notice of Annual General Meeting:Proxy Form
06 Oct 2020 Download PDF
Corporate Governance Statement and Appendix 4G
06 Oct 2020 Download PDF
Annual Report to shareholders
06 Oct 2020 Download PDF
Second Potential Blockbuster Drug Added to PYC’s Pipeline
06 Oct 2020 Download PDF
Annual Financial Statements June 2020
15 Sep 2020 Download PDF
Creation of Novel Gene Therapy Delivery Technology
08 Sep 2020 Download PDF
Appendix 4E Preliminary Final Report
31 Aug 2020 Download PDF
Appointment of world-renowned Chief Scientific Officer
19 Aug 2020 Download PDF
Shareholder Update August 2020
14 Aug 2020 Download PDF
Shareholder Update – Forward View 2020 Milestones
05 Aug 2020 Download PDF
Investor Call – 8am AWST – Wednesday 12 August 2020
03 Aug 2020 Download PDF
June 2020 Quarterly Activity Report and Cashflow
30 Jul 2020 Download PDF
Successful Dose Response & Toxicity Studies in Lead Program
22 Jul 2020 Download PDF
Appendix 2A
09 Jul 2020 Download PDF
Appendix 3G
30 Jun 2020 Download PDF
Investor Presentation
22 Jun 2020 Download PDF
Change of Director’s Interest Notice x 2
16 Jun 2020 Download PDF
Change in substantial holding
16 Jun 2020 Download PDF
PYC Recruits High Profile Chief Medical Officer to US Ops
09 Jun 2020 Download PDF
Appendix 3G
04 Jun 2020 Download PDF
World Class Results – Lions Eye Institute News Release
25 May 2020 Download PDF
March 2020 Quarterly Activities and Cash Flow Report
29 Apr 2020 Download PDF
Efficacy and Toxicity Studies Presentation
15 Apr 2020 Download PDF
Successful Toxicity Results Confirm Safety Advantage
08 Apr 2020 Download PDF
Trading Halt
30 Mar 2020 Download PDF
Investor Call 9.00am AWST Wed 1 April 2020
30 Mar 2020 Download PDF
Becoming a substantial holder
20 Mar 2020 Download PDF
Half Yearly Report and Accounts
28 Feb 2020 Download PDF
Investor Presentation
24 Feb 2020 Download PDF
Appendix 3G
19 Feb 2020 Download PDF
Appendix 3G
18 Feb 2020 Download PDF
NHMRC Grand for Identifying new Antisense Drugs
17 Feb 2020 Download PDF
Visual Evidence of Lead Drugs Efficacy
16 Feb 2020 Download PDF
Appendix 3G
16 Feb 2020 Download PDF
Initial Director’s Interest Notice
12 Feb 2020 Download PDF
CEO Appointment & Establishment of US Office
12 Feb 2020 Download PDF
Investor Call 27 February 2020
05 Feb 2020 Download PDF
Appendix 4C – Quarterly
31 Jan 2020 Download PDF
Change of Share Registry
20 Jan 2020 Download PDF

2019

Quarterly Shareholder Update
06 Dec 2019 Download PDF
Drug Delivery Greater than 100% more Effective – Amended
05 Dec 2019 Download PDF
Change in Director’s Notice x 2
02 Dec 2019 Download PDF
Change in Substantial Holding_v2
02 Dec 2019 Download PDF
Change in Substantial Holding
02 Dec 2019 Download PDF
Drug Delivery Greater than 100%
29 Nov 2019 Download PDF
2019 AGM Chairman’s Address
27 Nov 2019 Download PDF
Change in Substantial Holding
27 Nov 2019 Download PDF
2019 AGM Presentation
19 Nov 2019 Download PDF
Completion of Retail Entitlement Offer
19 Nov 2019 Download PDF
Conclusion of Genentech Antimicrobial Collaboration
16 Nov 2019 Download PDF
PYC Increases Shareholding in Vision Pharma
14 Nov 2019 Download PDF
Change in Substantial Holding
12 Nov 2019 Download PDF
Change of Director’s Interest Notice
12 Nov 2019 Download PDF
Change in Substantial Holding
11 Nov 2019 Download PDF
Appendix 3B
31 Oct 2019 Download PDF
Entitlement Offer – Investor Presentation
31 Oct 2019 Download PDF
Notice Under Section 708AA
31 Oct 2019 Download PDF
$26.8M Fully Underwritten accelerated Entitlement Offer
31 Oct 2019 Download PDF
Trading Halt
31 Oct 2019 Download PDF
Quarterly Shareholder Update and Appendix 4C
30 Oct 2019 Download PDF
Corporate Governance Statement
21 Oct 2019 Download PDF
Drug Delivery Greater than 100%
21 Oct 2019 Download PDF
Annual Report to Shareholders
18 Oct 2019 Download PDF
Appendix 4G
18 Oct 2019 Download PDF
Notice of Annual General Meeting : Proxy Form
18 Oct 2019 Download PDF
Investor Relations Presentation
15 Oct 2019 Download PDF
Presentation Oligonucleotide Therapeutics Society Meeting
14 Oct 2019 Download PDF
Succesfful Major Milestone – Human Retina in a Dish Model
09 Oct 2019 Download PDF
Strategic Partnership and Lead Program
01 Oct 2019 Download PDF
Trading Halt
30 Sep 2019 Download PDF
Successful Time-Course Studies in Animals
25 Sep 2019 Download PDF
Full Year Statutory Accounts
17 Sep 2019 Download PDF
Scientific Advisory Board Appointment
13 Sep 2019 Download PDF
Investor Relations Presentation
04 Sep 2019 Download PDF
Successful Competitive Drug Evaluation in Animals
03 Sep 2019 Download PDF
Preliminary Final Report
30 Aug 2019 Download PDF
Investor Call
23 Aug 2019 Download PDF
Successful Time – Course Studies in Animals
22 Aug 2019 Download PDF
Company Re-branding
09 Aug 2019 Download PDF
Response to ASX Aware Query
07 Aug 2019 Download PDF
Phylogica’s Technology is Effective in Human Cells
06 Aug 2019 Download PDF
Company Presentation – July 2019
24 Jul 2019 Download PDF
Operational Update and Appendix 4c
23 Jul 2019 Download PDF
Animal Models – 400% Outperformance of Gold Standard
23 Jul 2019 Download PDF
Break Through Animal Model Results
27 Jun 2019 Download PDF
March 2019 Quarterly Operational Update
29 Apr 2019 Download PDF
Change of Director’s Interest Notice
24 Apr 2019 Download PDF
Scientific Advisory Board Appointment
22 Mar 2019 Download PDF

Events

Upcoming Events Past Events

Upcoming Events

More events are coming soon

Past Events

Webcast: PYC Therapeutics Limited

01/14/2021 View Event

AGM 2020

11/06/2020 View Event

Turning RNA Research into Medicines Panel

02/17/2021 View Event

Select Area of Interest

Financial and Annual Reports Corporate Governance Charters Policies and Procedures

2021

There are no reports

2020

9th October 2020 – Annual Report
09 Oct 2020 Download PDF

2019

30th June 2019 Annual Report to Shareholders
18 Oct 2019 Download PDF

2018

30/06/2018 – Annual Report
30 Jun 2018 Download PDF

PYC Therapeutics Limited (“Company”) has adopted a Corporate Governance Plan which forms the basis of a comprehensive system of control and accountability for the administration of corporate governance.

The Board is committed to administering the policies and procedures with openness and integrity, pursuing the true spirit of corporate governance commensurate with the Company’s needs.

To the extent they are applicable to the Company, the Board has adopted the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations 3rd Edition (“Principles & Recommendations”).

A Corporate Governance Statement sets out details of the Company’s compliance with the Principles & Recommendations. Click here to read the ASX Corporate Governance Principles & Recommendations.

The Company is pleased to make the following information on its corporate governance practices available on this website.

CORPORATE GOVERNANCE STATEMENT
27 Jan 2021 Download PDF
CONSTITUTION – PYC THERAPEUTICS LIMITED
27 Jan 2021 Download PDF
RISK COMMITTEE
27 Jan 2021 Download PDF
REMUNERATION COMMITTEE
27 Jan 2021 Download PDF
NOMINATION COMMITTEE
27 Jan 2021 Download PDF
BOARD
27 Jan 2021 Download PDF
AUDIT COMMITTEE
27 Jan 2021 Download PDF
WHISTLEBLOWER POLICY
27 Jan 2021 Download PDF
TRADING POLICY
27 Jan 2021 Download PDF
SHAREHOLDER COMMUNICATION STRATEGY
27 Jan 2021 Download PDF
DIVERSITY POLICY
27 Jan 2021 Download PDF
DISCLOSURE – RISK MANAGEMENT
27 Jan 2021 Download PDF
DISCLOSURE – PERFORMANCE EVALUATION
27 Jan 2021 Download PDF
DISCLOSURE – CONTINUOUS DISCLOSURE
27 Jan 2021 Download PDF
DEFINITION OF INDEPENDENCE
27 Jan 2021 Download PDF
CORPORATE CODE OF CONDUCT
27 Jan 2021 Download PDF

Investor Relations and Media Contacts

Investors

Deborah Elson and Matthew DeYoung
Argot Partners
001.212.600.1902
deborah@argotpartners.com | matthew@argotpartners.com

Media

Leo Vartorella
Argot Partners
001.212.600.1902
leo@argotpartners.com

Discover more about our Pipeline

We are combining our proprietary CPP technology with world-leading expertise in PMO design to create a pipeline of highly precise, safe and effective combination drugs.

Our Pipeline